3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-one
• 英文别名: 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-one
• 化学式: C₁₁H₁₀N₂OS
• 分子量: 218.279
• InChiKey: YDKBMIFGWFISIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  58
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-one 在 谷胱甘肽 作用下， 以 aq. phosphate buffer 、 乙腈 为溶剂， 反应 24.0h， 以26%的产率得到2-(1,4,5,6-四氢-2-嘧啶)苯硫醇
  参考文献：
  名称：

  研究2-（2-巯基苯基）四氢嘧啶的可能前药结构：用嘧啶基苯并噻嗪和异噻唑并嘧啶骨架从抗HIV药物还原转化†

  摘要：

  3,4-二氢-2 H，6 H-嘧啶[1,2- c ] [1,3]苯并噻嗪-6-亚胺（PD 404182）和3,4-二氢-2 H-苯并[4,5]异噻唑啉[2,3- a]嘧啶是针对人类1型免疫缺陷病毒（HIV-1）感染的杂环抗逆转录病毒药物。基于这些独特支架之间抗HIV活性对病毒感染早期阶段的相似结构-活性关系，研究了生物测定条件下的转化。异噻唑并嘧啶骨架中独特的S–N键在GSH存在下于还原条件下立即裂解，生成硫酚衍生物。观察到PD 404182相似地快速转化为相同的硫酚衍生物，这表明嘧啶并苯并噻嗪和异噻唑并嘧啶骨架可以作为常见生物活性硫酚衍生物的前药形式发挥作用。

  DOI：

  10.1039/c5ob00301f
• 作为产物：
  描述：

  2-苯基-1,4,5,6-四氢嘧啶 在 氧气 、 copper diacetate 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 13.25h， 生成 3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-one
  参考文献：
  名称：

  简明合成和嘧啶的抗HIV活性[1,2 Ç ] [1,3]苯并噻嗪-6-亚胺及相关的三环杂环†

  摘要：

  3,4-二氢-2 H，6 H-嘧啶[1,2- c ] [1,3]苯并噻嗪-6-亚胺（PD 404182）是对多种病毒（包括HCV，HIV和猿猴免疫缺陷病毒）具有活性的杀病毒杂环化合物。使用我们开发的用于合成嘧啶并[1,2- c ] [1,3]苯并噻嗪-6-亚胺和相关三环衍生物的简便合成方法，对中心1,3-噻嗪-2-亚胺的平行结构进行了优化研究了PD 404182的核，苯部分和环am部分。取代6-6-6嘧啶[1,2- c具有5-6-6或6-6-5衍生物的] [1,3]苯并噻嗪-6-亚胺骨架导致抗HIV活性显着下降，并在9-或10-位引入了疏水基团提高了效能。此外，我们证明了PD 404182衍生物在病毒感染的早期发挥了抗HIV的作用。

  DOI：

  10.1039/c2ob25904d

文献信息

• Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
  作者：Marius Muth、Niklas Jänsch、Aleksandra Kopranovic、Andreas Krämer、Nathalie Wössner、Manfred Jung、Frank Kirschhöfer、Gerald Brenner-Weiß、Franz-Josef Meyer-Almes

  DOI：10.1016/j.bbagen.2019.01.001

  日期：2019.3

  Background: HDAC8 is an established target for T-cell lymphoma and childhood neuroblastoma. Benzothiazine-imines are promising HDAC8 inhibitors with unknown binding mechanism lacking a usual zinc binding group.Methods: In this study high-resolution and quantitative HPLC-coupled ESI-MS/MS techniques are combined with crystal structure determination and a variety of biochemical and computational methods to elucidate the reaction mechanism between benzothiazine-imine 1 and HDAC8.Results: 1) 1 is a covalent inhibitor of HDAC8; 2) inhibition is reversible in the presence of reducing agents; 3) C153 in the active site and C102 are involved in the inhibition mechanism; 4) 1 modifies various cysteines in HDAC8 forming either thiocyanates or mixed disulfides with 3; 5) 1 and 5 dock in close proximity to C153 within the active site. This is supposed to accelerate covalent inactivation particularly in HDAC8 and suggested as major determinant for the observed nanomolar potency and selectivity of 1.Conclusions: 1 and its analogs are interesting model compounds but unsuitable for therapeutic treatment due to their high unselective reactivity towards thiol groups. However, the postulated preceding non-covalent binding mode of 1 opens a door to optimized next generation compounds that combine potent and selective non-covalent recognition with low reactivity towards C153 at the active site of HDAC8.General significance: 1 represents a completely new class of inhibitors for HDAC8. Initial non-covalent interaction at the bottom of the active site is suggested to be the key for its selectivity. Further optimization of non covalent interaction and thiol-reactivity provides opportunities to develop therapeutic useful covalent HDAC8 inhibitors.
• Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles
  作者：Tsukasa Mizuhara、Shinya Oishi、Hiroaki Ohno、Kazuya Shimura、Masao Matsuoka、Nobutaka Fujii

  DOI：10.1039/c2ob25904d

  日期：——

  and simian immunodeficiency virus. Using facile synthetic approaches that we developed for the synthesis of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic derivatives, the parallel structural optimizations of the central 1,3-thiazin-2-imine core, the benzene part, and the cyclic amidine part of PD 404182 were investigated. Replacement of the 6-6-6 pyrimido[1,2-c][1,3]benzothiazin-6-imine

  3,4-二氢-2 H，6 H-嘧啶[1,2- c ] [1,3]苯并噻嗪-6-亚胺（PD 404182）是对多种病毒（包括HCV，HIV和猿猴免疫缺陷病毒）具有活性的杀病毒杂环化合物。使用我们开发的用于合成嘧啶并[1,2- c ] [1,3]苯并噻嗪-6-亚胺和相关三环衍生物的简便合成方法，对中心1,3-噻嗪-2-亚胺的平行结构进行了优化研究了PD 404182的核，苯部分和环am部分。取代6-6-6嘧啶[1,2- c具有5-6-6或6-6-5衍生物的] [1,3]苯并噻嗪-6-亚胺骨架导致抗HIV活性显着下降，并在9-或10-位引入了疏水基团提高了效能。此外，我们证明了PD 404182衍生物在病毒感染的早期发挥了抗HIV的作用。
• Investigations of possible prodrug structures for 2-(2-mercaptophenyl)tetrahydropyrimidines: reductive conversion from anti-HIV agents with pyrimidobenzothiazine and isothiazolopyrimidine scaffolds
  作者：Shiho Okazaki、Shinya Oishi、Tsukasa Mizuhara、Kazuya Shimura、Hiroto Murayama、Hiroaki Ohno、Masao Matsuoka、Nobutaka Fujii

  DOI：10.1039/c5ob00301f

  日期：——

  3,4-Dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (PD 404182) and 3,4-dihydro-2H-benzo[4,5]isothiazolo[2,3-a]pyrimidine are the heterocyclic antiretroviral agents against human immunodeficiency virus type 1 (HIV-1) infection. On the basis of similar structure–activity relationships of anti-HIV activities toward the early-stage of viral infection between these unique scaffolds, the transformations

  3,4-二氢-2 H，6 H-嘧啶[1,2- c ] [1,3]苯并噻嗪-6-亚胺（PD 404182）和3,4-二氢-2 H-苯并[4,5]异噻唑啉[2,3- a]嘧啶是针对人类1型免疫缺陷病毒（HIV-1）感染的杂环抗逆转录病毒药物。基于这些独特支架之间抗HIV活性对病毒感染早期阶段的相似结构-活性关系，研究了生物测定条件下的转化。异噻唑并嘧啶骨架中独特的S–N键在GSH存在下于还原条件下立即裂解，生成硫酚衍生物。观察到PD 404182相似地快速转化为相同的硫酚衍生物，这表明嘧啶并苯并噻嗪和异噻唑并嘧啶骨架可以作为常见生物活性硫酚衍生物的前药形式发挥作用。